Key Takeaways
- • Partners Group Private Equity Limited's NAV fell 2.5% in April to EUR 12.26 per share (EUR 830.13 million total), driven by portfolio revaluations (-1.8%) and adverse currency movements (-0.7%).
- • Pharmathen, a developer of advanced drug delivery technologies, was written down to zero following an FDA Import Alert that restricts US market supply, rendering the enterprise value insufficient to cover existing debt.
- • US Infrastructure Corporation (USIC) valuation was prudently reduced to reflect lower anticipated earnings growth following customer insourcing initiatives and operational headwinds, though Partners Group continues working with management on recovery initiatives.
- • Distribution activity remained robust with EUR 23.9 million received in April, primarily from the sale of Clario to Thermo Fisher Scientific at USD 9.4 billion enterprise value; Clario provides digital clinical trial solutions including wearable monitoring and remote patient data collection.
- • Listed assets provided partial offset to portfolio declines, demonstrating the diversification benefit within the fund's mixed holdings strategy.
Summary
Partners Group Private Equity Limited reported a 2.5% NAV decline in April, with net asset value falling to EUR 12.26 per share and total fund assets reaching EUR 830.13 million. The decline was primarily attributable to portfolio revaluations reducing NAV by 1.8%, compounded by negative currency movements of 0.7%. These headwinds were partially mitigated by positive performance in listed asset positions held within the fund.
The NAV contraction was concentrated in two significant portfolio holdings. Pharmathen, an advanced drug delivery technology developer, was written down to zero following regulatory setbacks. The company became subject to an FDA Import Alert restricting supply access to the US market, a critical revenue channel. Given Pharmathen's ongoing operational turnaround initiatives, Partners Group determined that the revised enterprise value outlook would be insufficient to service the company's existing debt obligations, necessitating a full write-down. In parallel, US Infrastructure Corporation, which provides underground utility locating services, experienced a material valuation reduction reflecting lower anticipated earnings growth driven by customer insourcing activities and operational headwinds. Despite these challenges, Partners Group maintained active engagement with USIC's board and management on operational and commercial initiatives to support future value recovery.
Distribution activity demonstrated underlying portfolio strength, with the fund receiving EUR 23.9 million in proceeds during April. The primary driver was the sale of Clario, a US-based health technology platform that enhances clinical trial execution through digital data collection and analysis, including wearable devices, imaging, and remote monitoring capabilities. Clario was acquired by Thermo Fisher Scientific at an enterprise value of USD 9.4 billion, representing a significant liquidity event for the fund. This robust distribution activity, combined with listed asset gains, provided substantial offset to the private equity portfolio declines, illustrating the value of diversification across asset classes within the vehicle's structure.
The NAV contraction was concentrated in two significant portfolio holdings. Pharmathen, an advanced drug delivery technology developer, was written down to zero following regulatory setbacks. The company became subject to an FDA Import Alert restricting supply access to the US market, a critical revenue channel. Given Pharmathen's ongoing operational turnaround initiatives, Partners Group determined that the revised enterprise value outlook would be insufficient to service the company's existing debt obligations, necessitating a full write-down. In parallel, US Infrastructure Corporation, which provides underground utility locating services, experienced a material valuation reduction reflecting lower anticipated earnings growth driven by customer insourcing activities and operational headwinds. Despite these challenges, Partners Group maintained active engagement with USIC's board and management on operational and commercial initiatives to support future value recovery.
Distribution activity demonstrated underlying portfolio strength, with the fund receiving EUR 23.9 million in proceeds during April. The primary driver was the sale of Clario, a US-based health technology platform that enhances clinical trial execution through digital data collection and analysis, including wearable devices, imaging, and remote monitoring capabilities. Clario was acquired by Thermo Fisher Scientific at an enterprise value of USD 9.4 billion, representing a significant liquidity event for the fund. This robust distribution activity, combined with listed asset gains, provided substantial offset to the private equity portfolio declines, illustrating the value of diversification across asset classes within the vehicle's structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.